John A Heit1, Brian D Lahr2, Aneel A Ashrani3, Tanya M Petterson2, Kent R Bailey2. 1. Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA; Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. Electronic address: heit.john@mayo.edu. 2. Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. 3. Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Abstract
BACKGROUND: Predictors of venous thromboembolism (VTE) recurrence are uncertain. OBJECTIVE: To identify predictors of VTE recurrence, adjusted for treatments and interim exposures. MATERIALS AND METHODS: Using Rochester Epidemiology Project resources, all Olmsted County, MN residents with objectively-diagnosed incident VTE over the 13-year period, 1988-2000, who survived ≥1day were followed for first objectively-diagnosed VTE recurrence. For all patients with recurrence, and a random sample of all surviving incident VTE patients (n=415), we collected demographic and baseline characteristics, treatments and interim exposures. In a case-cohort study design, demographic, baseline, treatment and interim exposure characteristics were tested as potential predictors of VTE recurrence using time-dependent Cox proportional hazards modeling. RESULTS: Among 1262 incident VTE patients, 306 developed recurrence over 6,440 person-years. Five-year recurrence rates, overall and for cancer-associated, idiopathic and non-cancer secondary VTE, were 24.5%, 43.4%, 27.3% and 18.1%, respectively. In multivariable analysis, interim hospitalization, active cancer, pregnancy, central venous catheter and respiratory infection were associated with increased hazards of recurrence, and warfarin and aspirin were associated with reduced hazards. Adjusting for treatments and these interim risk factors, male sex, baseline active cancer and failure to achieve a therapeutic aPTT in the first 24hours were independently associated with increased hazards of VTE recurrence over the entire follow-up period, while the hazards of recurrence for patient age, chronic lung disease, leg paresis, prior superficial vein thrombosis and idiopathic VTE varied over the follow-up period. CONCLUSIONS: Baseline and interim exposures can stratify VTE recurrence risk and may be useful for directing secondary prophylaxis.
BACKGROUND: Predictors of venous thromboembolism (VTE) recurrence are uncertain. OBJECTIVE: To identify predictors of VTE recurrence, adjusted for treatments and interim exposures. MATERIALS AND METHODS: Using Rochester Epidemiology Project resources, all Olmsted County, MN residents with objectively-diagnosed incident VTE over the 13-year period, 1988-2000, who survived ≥1day were followed for first objectively-diagnosed VTE recurrence. For all patients with recurrence, and a random sample of all surviving incident VTEpatients (n=415), we collected demographic and baseline characteristics, treatments and interim exposures. In a case-cohort study design, demographic, baseline, treatment and interim exposure characteristics were tested as potential predictors of VTE recurrence using time-dependent Cox proportional hazards modeling. RESULTS: Among 1262 incident VTEpatients, 306 developed recurrence over 6,440 person-years. Five-year recurrence rates, overall and for cancer-associated, idiopathic and non-cancer secondary VTE, were 24.5%, 43.4%, 27.3% and 18.1%, respectively. In multivariable analysis, interim hospitalization, active cancer, pregnancy, central venous catheter and respiratory infection were associated with increased hazards of recurrence, and warfarin and aspirin were associated with reduced hazards. Adjusting for treatments and these interim risk factors, male sex, baseline active cancer and failure to achieve a therapeutic aPTT in the first 24hours were independently associated with increased hazards of VTE recurrence over the entire follow-up period, while the hazards of recurrence for patient age, chronic lung disease, leg paresis, prior superficial vein thrombosis and idiopathic VTE varied over the follow-up period. CONCLUSIONS: Baseline and interim exposures can stratify VTE recurrence risk and may be useful for directing secondary prophylaxis.
Authors: R D Hull; G E Raskob; J Hirsh; R M Jay; J R Leclerc; W H Geerts; D Rosenbloom; D L Sackett; C Anderson; L Harrison Journal: N Engl J Med Date: 1986-10-30 Impact factor: 91.245
Authors: Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Walter A Rocca Journal: Am J Epidemiol Date: 2011-03-23 Impact factor: 4.897
Authors: Paul A Kyrle; Erich Minar; Christine Bialonczyk; Mirko Hirschl; Ansgar Weltermann; Sabine Eichinger Journal: N Engl J Med Date: 2004-06-17 Impact factor: 91.245
Authors: James Douketis; Alberto Tosetto; Maura Marcucci; Trevor Baglin; Benilde Cosmi; Mary Cushman; Paul Kyrle; Daniela Poli; R Campbell Tait; Alfonso Iorio Journal: BMJ Date: 2011-02-24
Authors: Aneel A Ashrani; Rachel E Gullerud; Tanya M Petterson; Randolph S Marks; Kent R Bailey; John A Heit Journal: Thromb Res Date: 2016-01-05 Impact factor: 3.944
Authors: Wei Huang; Robert J Goldberg; Frederick A Anderson; Alexander T Cohen; Frederick A Spencer Journal: J Thromb Thrombolysis Date: 2016-04 Impact factor: 2.300
Authors: Banne Nemeth; Willem M Lijfering; Rob G H H Nelissen; Inger B Schipper; Frits R Rosendaal; Saskia le Cessie; Suzanne C Cannegieter Journal: JAMA Netw Open Date: 2019-05-03
Authors: M José Martínez-Zapata; Alexander G Mathioudakis; Shaker A Mousa; Rupert Bauersachs Journal: Clin Appl Thromb Hemost Date: 2017-03-14 Impact factor: 2.389